CME Presentations




  • Christopher P. Cannon, MD

    Christopher P. Cannon, MD

    Christopher P. Cannon, MD

    Professor of Medicine

    Christopher P. Cannon, MD, is a professor of medicine at Harvard Medical School and a senior physician in the Cardiovascular Division at Brigham and Women’s Hospital in Boston, Massachusetts, where he currently serves as education director of the Cardiovascular Medicine Innovation group. He has worked for 25 years as an investigator in the TIMI Study Group, then for 5 years with the Harvard Clinical Research Institute (now Baim Institute). Dr Cannon has published over 1000 original articles, reviews or book chapters in the field of acute coronary syndromes and prevention, has authored or edited 18 books, and has been principal investigator of more than 20 multicenter clinical trials. He earned his medical degree from Columbia University College of Physicians and Surgeons in New York.
  • Christie M. Ballantyne, MD

    Christie M. Ballantyne, MD

    Christie M. Ballantyne, MD

    Professor of Medicine

    Christie M. Ballantyne, MD, is vice chair of research for the Department of Medicine, chief, sections of cardiology and cardiovascular research, and director of the Lipid Metabolism and Atherosclerosis Clinic Center for Cardiometabolic Disease Prevention at Baylor College of Medicine in Houston, Texas. Dr Ballantyne is a leading expert on lipids, atherosclerosis and heart disease prevention. He is an established investigator for the American Heart Association and receives funding from the National Institutes of Health for research and clinical trials. Dr Ballantyne is an editorial director for, serves on the editorial board for Circulation, and has published extensively on atherosclerosis, lipids and inflammation. He received his MD from Baylor College of Medicine.

CME Information

Role of PCSK9 Inhibitors in the Management of Patients with Familial Hypercholesterolemia

Joslin Diabetes Center Logo Joslin Diabetes Center Logo


At the conclusion of this activity, participants will be able to:
  • Recognize the warning signs of Familial Hypercholesterolemia (FH) in patients who present with high cholesterol
  • Devise medical treatment plans in line with evidence-based guidelines for LDL-C management in patients with FH
  • Outline strategies to address barriers to access for PCSK9 inhibitors for patients with FH with poor control of total cholesterol and LDL-C levels
At the conclusion of all NLA-accredited activities, all participants should be able to:
  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team

Activity Format

Enduring Internet Activity

Release Date

June 26, 2019

Expiration Date

December 26, 2019


There is no fee for this activity.

Target Audience

This activity is designed to meet the needs of cardiologists, internal medicine physicians, primary care physicians, endocrinologists, physician assistants, nurse practitioners, nurses, and pharmacists.

Type of Activity


Criteria For Success

To participate in the activity, go to To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the posttest. If you have questions about this CME/CE activity, please contact the NLA at Please claim credit by December 26, 2019.

Commercial Support

This activity is supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals.

Credit Designation

Credit provided by the National Lipid Association In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and PlatformQ Health Education, LLC. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement

The National Lipid Association designates this Internet Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.


ACPE Logo Universal Activity Number – JA0007192-9999-19-016-L01-P (Application) This Activity has been approved for 1.00 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education. Nursing The maximum number of hours awarded for the CE activity is 1.0 contact hours For the advanced practice nurse, this activity has 0.2 contact hours of pharmacotherapy content.  
Christie M. Ballantyne, MD Professor of Medicine Chief, Section of Cardiovascular Research Chief, Section of Cardiology Director, Lipid Metabolism and Atherosclerosis Clinic Center for Cardiometabolic Disease Prevention Baylor College of Medicine Houston, TX Christopher P. Cannon, MD Education Director, Cardiovascular Innovation, Cardiology Division Brigham and Women’s Hospital Professor of Medicine Harvard Medical School Boston, MA
Name Relationship Company
Ballantyne, Christie •Grant/Research Support •Consultant •Provisional patent •Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, NIH, ADA, AHA •Abbott Diagnostic, Akcea, Amarin, Amgen, Arrowhead, Astra Zeneca, Boehringer Ingelheim, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, Sanofi-Synthelabo •“Biomarkers to Improve Prediction of Heart Failure Risk” (patent no. 61721475) filed by Baylor College of Medicine and Roche
Cannon, Christopher •Grant/Research Support •Consultant •Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck •Aegerion, Alnylam, Amarin, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, Eisai, Innovent, Janssen, Kowa, Merck, Pfizer, Regeneron, Sanofi
PlatformQ Health Education, LLC N/A Nothing to Disclose
NLA N/A Nothing to Disclose
Susan Halli Demeter, DNP, FNP-BC, CLS, FNLA N/A Nothing to Disclose

Disclosure of Unlabled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

Estimated Time to Complete

This activity consists of one session, which should take approximately 1 hour to complete.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Contact Information

Accreditation Support: Please contact the National Lipid Association at Technical Support: For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at